GlassScriptPhysician profile
Tony Hoang
NPI 1609069947
$4,294.52
in general payments reported to CMS, 2019-2025
30 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $653 · 2021: $723 · 2022: $937 · 2023: $926 · 2024: $280 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350 · Travel and Lodging: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.57 |
| Travel and Lodging | $245.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $901.16 | 2019-2024 | |
| Hologic Sales and Service, LLC | $598.05 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $395.79 | 2019-2022 | |
| Acessa Health INC. | $245.70 | 2023 | Acessa Provu System |
| Evofem Biosciences, INC. | $208.78 | 2020-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $195.43 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $183.72 | 2023-2025 | Myfembree, Gemtesa |
| Abbott Laboratories | $147.22 | 2021-2025 | Proclaim, Eterna |
| Acell, INC. | $144.07 | 2020 | |
| Myovant Sciences INC. | $141.47 | 2021-2022 | |
| Pfizer INC. | $135.62 | 2022-2024 | |
| Minerva Surgical, INC | $104.09 | 2019-2025 | |
| Sage Therapeutics, LLC | $96.29 | 2019-2025 | Zurzuvae |
| Shield Therapeutics INC | $90.07 | 2023-2025 | Accrufer |
| Stimlabs LLC | $77.53 | 2025 | Corplex P |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $76.24 | 2019 | |
| Avion Pharmaceuticals | $76.00 | 2019-2021 | |
| Organon LLC | $73.04 | 2021-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $70.56 | 2019-2021 | |
| Ascend Therapeutics US, LLC | $68.54 | 2021-2023 | |
| Lupin INC. | $56.01 | 2020-2021 | |
| Astellas Pharma US INC | $53.53 | 2024-2025 | Veozah |
| Channel Medsystems, INC. | $24.46 | 2022 | |
| Agile Therapeutics, INC. | $24.13 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.85 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $20.51 | 2024 | |
| Allergan, INC. | $17.88 | 2020 | |
| Glaxosmithkline, LLC. | $16.24 | 2022 | |
| Smith+Nephew, INC. | $14.98 | 2023 | Grafix Pl |
| Novo Nordisk INC | $14.56 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.